Alimentiv’s model attracts eyes across the medical community and beyond. Here are the latest stories people are telling about us, our mission and our unique Health Trust.
London, ON, CANADA, Release: August 12, 2021 –Alimentiv, Inc. announced today the launch of their new eTMF solution in partnership with Veeva Vault eTMF, offering sponsors real-time data and secure access to all clinical documentation throughout the clinical trial lifecycle. As part of its strategy to modernize its technology landscape, Alimentiv selected Vault eTMF to improve […]read more
Join our expert panel where they will discuss inflammatory bowel disease and NASH, two therapeutic areas that histopathology uses to determine eligibility and/or primary outcome measures. Our four experts will provide presentations on topics including Histopathology as a treatment target in IBD: Aspiration or Reality? Measuring histopathology in IBD trials Histopathology as a treatment target […]read more
Alimentiv is pleased to announce that Mike Reffeitt joined Alimentiv Inc. as the new Chief Financial Officer, effective Monday, May 3, 2021. Mike will be working alongside the executive team to drive the business and strategy of the Alimentiv group of companies forward and support our corporate operations teams including IT, legal, quality, facilities, and […]read more
London, ON, CANADA, Release: April 14, 2021 – Alimentiv Health Trust, the parent company of Alimentiv, Inc. (formerly Robarts Clinical Trials), a specialized global gastrointestinal (GI) contract research organization (CRO), and McDougall Scientific Ltd., a niche CRO, announced today the launch of AcelaBio, a commercial state-of-the-art research laboratory delivering histopathology and precision medicine services for […]read more